Soft Tissue Sarcoma
Conditions
Keywords
Sarcoma, questionnaire, doxorubicin plus ifosfamide (AI)
Brief summary
Assessments (survey data) in this study are designed to sample the symptom burden of patients undergoing adjuvant and neoadjuvant chemotherapy in the hospital. There will be no change in the treatment plan for these patients.
Interventions
OTHERQuestionnaires
Subjects will be given a series of questionnaires to assess the effect of AI chemotherapy, and the possible role of tumor load, on the amount of symptoms. The extent of nausea, vomiting, fatigue, anxiety, sleep disturbance, and cognitive changes will be measured. In adjuvant chemotherapy patients, we will also assess the relationship between tumor size and amount of chemotherapy-induced symptoms. These questionnaires will involve the following assessments: Demographic & health Trait anxiety Quality of life Nausea Expectations Anxiety & total mood disturbance Nausea & vomiting Multiple symptoms
Sponsors
University of Pittsburgh
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who are receiving doxorubicin plus ifosfamide (AI)
Exclusion criteria
* There is no
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the extent of symptom burden and quality of life in sarcoma patients receiving AI chemotherapy. | 2 years |
Countries
United States
Outcome results
None listed